Vaccine Development and Future for Helicobacter pylori.
10.7704/kjhugr.2016.16.3.134
- Author:
Soo Jeong CHO
1
Author Information
1. Center for Gastric Cancer, National Cancer Center, Goyang, Korea. crystal522@ncc.re.kr
- Publication Type:Clinical Trial ; Review
- Keywords:
Helicobacter pylori;
Vaccine
- MeSH:
Adenocarcinoma;
China;
Gastritis;
Helicobacter pylori*;
Helicobacter*;
Lymphoma, B-Cell, Marginal Zone;
Peptic Ulcer;
Vaccination
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2016;16(3):134-138
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Helicobacter pylori is one of the most common gastric pathogens, affecting at least half the world's population, and is strongly associated with gastritis, peptic ulcer, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue lymphoma. Vaccination against H. pylori has been challenging because of its low efficacy, lack of information about protective immunity, and disappointing clinical studies. A recent phase 3 clinical trial in China was reported to be successful to test prophylactic vaccination against H. pylori, which caused growing interest in the vaccine development against H. pylori. Here, we review literatures regarding vaccination against H. pylori.
